116 related articles for article (PubMed ID: 9702212)
1. Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells.
Distefano M; Scambia G; Ferlini C; Gallo D; De Vincenzo R; Filippini P; Riva A; Bombardelli E; Mancuso S
Anticancer Drug Des; 1998 Jul; 13(5):489-99. PubMed ID: 9702212
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative activity of colchicine analogues on MDR-positive and MDR-negative human cancer cell lines.
De Vincenzo R; Scambia G; Ferlini C; Distefano M; Filippini P; Riva A; Bombardelli E; Pocar D; Gelmi ML; Benedetti Panici P; Mancuso S
Anticancer Drug Des; 1998 Jan; 13(1):19-33. PubMed ID: 9474240
[TBL] [Abstract][Full Text] [Related]
3. Biological evaluation on different human cancer cell lines of novel colchicine analogs.
De Vincenzo R; Ferlini C; Distefano M; Gaggini C; Riva A; Bombardelli E; Morazzoni P; Danieli B; Capelli G; Mancuso S; Scambia G
Oncol Res; 1999; 11(3):145-52. PubMed ID: 10527074
[TBL] [Abstract][Full Text] [Related]
4. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
5. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
6. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
[TBL] [Abstract][Full Text] [Related]
8. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of newly developed chalcone analogues in human cancer cells.
De Vincenzo R; Ferlini C; Distefano M; Gaggini C; Riva A; Bombardelli E; Morazzoni P; Valenti P; Belluti F; Ranelletti FO; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2000; 46(4):305-12. PubMed ID: 11052628
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of taxol on two human cancer cell lines.
Banerjee S; Fallis AG; Brown DL
Oncol Res; 1997; 9(5):237-48. PubMed ID: 9306431
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
12. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells.
Distefano M; Scambia G; Ferlini C; Gaggini C; De Vincenzo R; Riva A; Bombardelli E; Ojima I; Fattorossi A; Panici PB; Mancuso S
Int J Cancer; 1997 Sep; 72(5):844-50. PubMed ID: 9311603
[TBL] [Abstract][Full Text] [Related]
13. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.
Oldham EA; Li C; Ke S; Wallace S; Huang P
Int J Oncol; 2000 Jan; 16(1):125-32. PubMed ID: 10601557
[TBL] [Abstract][Full Text] [Related]
14. Difluoromethylornithine antagonizes taxol cytotoxicity in MCF-7 human breast cancer cells.
Das B; Rao AR; Madhubala R
Oncol Res; 1997; 9(11-12):565-72. PubMed ID: 9563003
[TBL] [Abstract][Full Text] [Related]
15. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro.
Michalakis J; Georgatos SD; de Bree E; Polioudaki H; Romanos J; Georgoulias V; Tsiftsis DD; Theodoropoulos PA
Ann Surg Oncol; 2007 Mar; 14(3):1220-8. PubMed ID: 17206477
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells.
Gorodetsky R; Levdansky L; Ringel I; Vexler A
Radiat Res; 1998 Sep; 150(3):283-91. PubMed ID: 9728657
[TBL] [Abstract][Full Text] [Related]
17. Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines.
Lui WY; Chang YF; Li LL; Ho LK; Su TL; Chen JY; Liu TY; P'Eng FK; Chi CW
Anticancer Res; 1998; 18(5A):3339-45. PubMed ID: 9858906
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy.
Sui M; Dziadyk JM; Zhu X; Fan W
Clin Cancer Res; 2004 Jul; 10(14):4848-57. PubMed ID: 15269161
[TBL] [Abstract][Full Text] [Related]
19. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis.
Poma P; Notarbartolo M; Labbozzetta M; Maurici A; Carina V; Alaimo A; Rizzi M; Simoni D; D'Alessandro N
Int J Mol Med; 2007 Sep; 20(3):329-35. PubMed ID: 17671737
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines.
Faried A; Faried LS; Kimura H; Sohda M; Nakajima M; Miyazaki T; Kato H; Kanuma T; Kuwano H
Cancer Chemother Pharmacol; 2006 Feb; 57(3):301-8. PubMed ID: 16028102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
